This 2017 review article examines the association between statin therapy and the risk of developing type 2 diabetes mellitus (T2DM). It synthesizes data from population-based studies, randomized clinical trials, mechanistic metabolic studies, and Mendelian randomization analyses. Statins were associated with a 9%–12% increased risk of diabetes in randomized controlled trials
This 2016 editorial discusses the implications of the HOPE-3 trial, which evaluated the efficacy of rosuvastatin 10 mg daily in preventing cardiovascular events among intermediate-risk individuals without prior cardiovascular disease. The trial demonstrated a 24% relative risk reduction in major cardiovascular events with rosuvastatin compared to placebo, translating to an
This post hoc analysis of the IDEAL trial examined 8,888 patients with prior myocardial infarction randomized to high-dose atorvastatin (80 mg/day) or moderate-dose simvastatin (20–40 mg/day) over a median of 4.8 years. Results showed a significantly lower incidence of peripheral arterial disease (PAD) in the atorvastatin group (2.2%) compared to
This population-based cohort study from France included 7,484 community-dwelling adults aged 65 years and older without a history of vascular events. It aimed to assess whether lipid-lowering drugs (mainly statins and fibrates) reduce the long-term risk of stroke and coronary heart disease (CHD) in a primary prevention setting. Over a
This expert commentary reviews the concerns surrounding statin therapy in adults aged 75 and older, particularly in the context of primary prevention of cardiovascular disease (CVD). While statins are proven to reduce cardiovascular events in younger populations, the evidence in older adults is less definitive, especially for those without established
This 2013 retrospective cohort study by Mansi et al. investigated the association between statin use and musculoskeletal conditions in a military population. Using propensity score matching, 6,967 statin users were compared with 6,967 non-users. Results showed that statin users had significantly higher odds of being diagnosed with musculoskeletal diseases (OR
This 2022 review explores the multifaceted molecular actions of statins beyond their primary role in lowering LDL cholesterol. While statins are effective in reducing cardiovascular events, they also exhibit pleiotropic effects, including anti-inflammatory and antitumor activities. However, these benefits are accompanied by potential adverse effects such as myopathy, new-onset type
This 2013 commentary discusses the potential role of statins in cancer prevention and treatment. It references a Danish nationwide population-based cohort study that found statin users had a 15% reduction in both all-cause and cancer-specific mortality compared to non-users. Improved survival was observed in 13 out of 27 cancer subtypes,
This 2018 retrospective cohort study evaluated 5,416 ovarian cancer patients to investigate the association between statin use and overall survival. The study found that statin use correlated with a significant improvement in overall survival, particularly in patients with non-serous histologic subtypes. The proposed mechanisms include statins’ anti-inflammatory, anti-proliferative, and pro-apoptotic
This 2020 review article explores the growing body of evidence supporting the use of statins in both cancer prevention and treatment. Statins, through inhibition of the HMG-CoA reductase pathway, exhibit antiproliferative, pro-apoptotic, anti-angiogenic, and immunomodulatory effects in multiple cancer types such as breast, prostate, lung, colorectal, and ovarian cancers. Their
